Cargando…

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19

This report shows a case of corneal transplant rejection after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), short after receiving the BNT162b2 vaccine, in a patient who had undergone keratoplasty more than 20 years ago, with no previous episodes of rejection and...

Descripción completa

Detalles Bibliográficos
Autores principales: Eduarda Andrade e Andrade, Maria, Rodrigues, Juliane Cardoso, Junior, Elvio Ferreira, de Lima, Mario Henrique Camargos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672786/
https://www.ncbi.nlm.nih.gov/pubmed/35918988
http://dx.doi.org/10.4103/ijo.IJO_1021_22
Descripción
Sumario:This report shows a case of corneal transplant rejection after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), short after receiving the BNT162b2 vaccine, in a patient who had undergone keratoplasty more than 20 years ago, with no previous episodes of rejection and no other factor that could lead to the findings on his examinations. After treatment with high doses of topic, oral, and sub-conjunctival corticoids, the patient had a favorable therapeutic response. The signs of corneal transplant rejection must be oriented to the patients and the causing factors actively searched by ophthalmologists so that treatment is rapidly initiated and sequels are avoided. This report raises the question if these events are correlated and whether the patient should receive the second dose of the vaccine against SARS-CoV-2 or not.